Aberrant pre-mRNA processing in cancer.

IF 12.6 1区医学 Q1 IMMUNOLOGY

Journal of Experimental Medicine Pub Date : 2024-11-04 Epub Date: 2024-09-24 DOI:10.1084/jem.20230891

Jeetayu Biswas, Leora Boussi, Eytan Stein, Omar Abdel-Wahab

引用次数: 0

Abstract

Dysregulation of the flow of information from genomic DNA to RNA to protein occurs within all cancer types. In this review, we described the current state of understanding of how RNA processing is dysregulated in cancer with a focus on mutations in the RNA splicing factor machinery that are highly prevalent in hematologic malignancies. We discuss the downstream effects of these mutations highlighting both individual genes as well as common pathways that they perturb. We highlight examples of how alterations in RNA processing have been harnessed for therapeutic intent as well as to promote the selective toxicity of cancer cells.

查看原文本刊更多论文

癌症中异常的前核糖核酸（pre-mRNA）加工。

从基因组 DNA 到 RNA 再到蛋白质的信息流失调发生在所有癌症类型中。在这篇综述中，我们描述了目前对 RNA 处理在癌症中如何失调的理解，重点是血液恶性肿瘤中高发的 RNA 剪接因子机制中的突变。我们讨论了这些突变的下游效应，重点介绍了单个基因及其扰乱的常见通路。我们将重点举例说明如何利用 RNA 处理过程的改变来达到治疗目的，以及如何促进癌细胞的选择性毒性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Experimental Medicine 医学-免疫学

CiteScore

26.60

自引率

1.30%

发文量

189

审稿时长

3-8 weeks

期刊介绍： Since its establishment in 1896, the Journal of Experimental Medicine (JEM) has steadfastly pursued the publication of enduring and exceptional studies in medical biology. In an era where numerous publishing groups are introducing specialized journals, we recognize the importance of offering a distinguished platform for studies that seamlessly integrate various disciplines within the pathogenesis field. Our unique editorial system, driven by a commitment to exceptional author service, involves two collaborative groups of editors: professional editors with robust scientific backgrounds and full-time practicing scientists. Each paper undergoes evaluation by at least one editor from both groups before external review. Weekly editorial meetings facilitate comprehensive discussions on papers, incorporating external referee comments, and ensure swift decisions without unnecessary demands for extensive revisions. Encompassing human studies and diverse in vivo experimental models of human disease, our focus within medical biology spans genetics, inflammation, immunity, infectious disease, cancer, vascular biology, metabolic disorders, neuroscience, and stem cell biology. We eagerly welcome reports ranging from atomic-level analyses to clinical interventions that unveil new mechanistic insights.